Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 1Agammaglobulinemia 1

Interventions

venetoclax 18Rituximab 14ibrutinib 13obinutuzumab 10acalabrutinib 10Specimen Handling 10Cyclophosphamide 9Biopsy 9zanubrutinib 8pirtobrutinib 6Magnetic Resonance Spectroscopy 5Lenalidomide 5idelalisib 4fludarabine phosphate 4Cyclosporine 4CT-P10 4Bendamustine Hydrochloride 4ARQ531 4Whole-Body Irradiation 3Vincristine 3Sirolimus 3Prednisone 3Mycophenolic Acid 3Doxorubicin 3tafasitamab 2pembrolizumab 2fludarabine 2Immunoglobulins 2Disulfides 2Cyclosporins 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Lymphocytic, Chronic, B-Cell × Panzyga × 30 days × Clear all
NCT04502030 2026-06-04

Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

Octapharma

Phase 3 Completed
247 enrolled
LymphoidOther hematologic neoplasm

Agammaglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡